Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice

Nature Immunology

Volumn 4, Issue 3, 2003, Pages 255-260

  Lamhamedi Cherradi, Salah Eddine ^a   Zheng, Shi Jun ^a   Maguschak, Kimberly A ^a   Peschon, Jacques ^b   Chen, Youhai H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; STREPTOZOCIN; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; GENE DELETION; IMMUNE RESPONSE; LIGATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; THYMOCYTE; TUMOR CELL;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOIMMUNE DISEASES; CELL DIFFERENTIATION; CLONAL DELETION; COLLAGEN; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OVALBUMIN; T-LYMPHOCYTES; THYMUS GLAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037338951     PISSN: 15292908     EISSN: None     Source Type: Journal    
DOI: 10.1038/ni894     Document Type: Article

References (53)

1. Singer, G.G. & Abbas, A.K. The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1, 365-371 (1994).
2. Kishimoto, H., Surh, C.D. & Sprent, J. A role for Fas in negative selection of thymocytes in vivo. J. Exp. Med. 187, 1427-1438 (1998).
3. Wiley, S.R. et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673-682 (1995).
4. Pan, G. et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277, 815-818 (1997).
5. Pan, G., Ni, J., Yu, G., Wei, Y.F. & Dixit, V.M. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett. 424, 41-45 (1998).
6. Schneider, P. et al. Characterization of two receptors for TRAIL. FEBS Lett. 416, 329-334 (1997).
7. Sheikh, M.S. et al. p53-dependent and -independent regulation of the death receptor KILLER/DRS gene expression in response to genotoxic stress and tumor necrosis factor α. Cancer Res. 58, 1593-1598 (1998).
8. Sheridan, J.P. et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277, 818-821 (1997).
9. Walczak H. et al, TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16, 5386-5397 (1997).
10. Screaton, G.R. et al. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr. Biol. 7, 693-696 (1997).
11. Sprick, M.R. et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12, 599-609 (2000).
12. Bodmer J.L. et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat. Cell Biol. 2, 241-243 (2000).
13. Zhang, X.D., Zhang, X.Y., Gray, C.P., Nguyen, T. & Hersey, P. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Cancer Res. 61, 7339-7348 (2001).
14. Deng, Y., Lin, Y. & Wu, X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev. 16, 33-45 (2002).
15. Abulencia, J.P., Gaspard, R., Quackenbush, J. & Konstantopoulos, K. Discovery and characterization of differentially regulated genes in the chondrocytic cell line T/C-28a2 under dynamic fluid shear. FASEB J. 16, A656-657 (2002).
16. Schneider, P. et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB. Immunity 7, 831-836 (1997).
17. Wu, G.S., Burns, T.F., Zhan, Y., Alnemri, E.S. & El-Deiry, W.S. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res. 59, 2770-2775 (1999).
18. Jeremias, I., Herr, I., Boehler, T. & Debatin, K.M. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur. J. Immunol. 28, 143-152 (1998).
19. Mariani, S.M. & Krammer, P.H. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur. J. Immunol. 28, 973-982 (1998).
20. Walczak, H. et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5, 157-163 (1999).
21. Ashkenazi, A. et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155-162 (1999).
22. Jo, M. et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 6, 564-567 (2000).
23. Simon, A.K. et al. Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: sensitivity of human thymocytes. Proc. Natl. Acad. Sci. USA 98, 5158-5163 (2001).
24. Martin-Villalba, A. et al. CD95 ligand (Fas-L/APO-IL) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J. Neurosci. 19, 3809-3817 (1999).
25. Sedger, L.M. et al. Characterization of the in vivo function of TNF-α-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur. J. Immunol. 32, 2246-2254 (2002).
26. Cretney, E. et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 168, 1356-1361 (2002).
27. Song, K. et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J. Exp. Med. 191, 1095-1104 (2000).
28. Zhang, Y. et al. In situ β cell death promotes priming of diabetogenic CD8 T lymphocytes. J. Immunol. 168, 1466-1472 (2002).
29. Horwitz, M.S., Ilic, A., Fine, C., Rodriguez, E. & Sarvetnick, N. Presented antigen from damaged pancreatic β cells activates autoreactive T cells in virus-mediated autoimmune diabetes. J. Clin. Invest. 109, 79-87 (2002).
30. Pechhold, K. et al. Low dose streptozotocin-induced diabetes in rat insulin promoter-mCD80-transgenic mice is T cell autoantigen-specific and CD28 dependent. J. Immunol. 166, 2531-2539 (2001).
31. Woodland, D.L., Happ, M.P., Gollob, K.J. & Palmer, E. An endogenous retrovirus mediating deletion of α β T cells? Nature 349, 529-530 (1991).
32. Tomonari, K., Fairchild, S. & Rosenwasser, O.A. Influence of viral superantigens on V β- and V α-specific positive and negative selection. Immunol. Rev. 131, 131-168 (1993).
33. Yui, K. et al. Molecular and functional properties of novel T cell subsets in C3H- gld/gld and nude mice. Implications for thymic and extrathymic maturation. Immunol. Rev. 104, 121-155 (1988).
34. Castro, J.E. et al. Fas modulation of apoptosis during negative selection of thymocytes. Immunity 5, 617-627 (1996).
35. Muller, K.P., Mariani, S.M., Matiba, B., Kyewski, B. & Krammer P.H. Clonal deletion of major histocompatibility complex class I-restricted CD4+CD8+ thymocytes in vitro is independent of the CD95 (APO-I/Fas) ligand. Eur. J. Immunol. 2S, 2996-2999 (1995).
36. Sytwu, H.K., Liblau, R.S. & McDevitt, H.O. The roles of Fas/APO-I (CD95) and TNF in antigen-induced programmed cell death in T cell receptor transgenic mice. Immunity 5, 17-30 (1996).
37. Page, D.M., Roberts, E.M., Peschon, J.J. & Hedrick, S.M. TNF receptor-deficient mice reveal striking differences between several models of thymocyte negative selection. J. Immunol. 160, 120-133 (1998).
38. Nitsch, R. et al. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 356, 827-828 (2000).
39. Green, D.R. & Reed, J.C. Mitochondria and apoptosis. Science 281, 1309-1312 (1998).
40. Zhang, J., Cado, D., Chen, A., Kabra, N.H. & Winoto, A. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature 392, 296-300 (1998).
41. Kuida, K. et al. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 94, 325-337 (1998).
42. Walsh, C.M. et al. A role for FADD in T cell activation and development. Immunity 8, 439-449 (1998).
43. Newton, K., Harris, A.W., Bath, M.L., Smith, K.G. & Strasser, A. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J. 17, 706-718 (1998).
44. Sentman, C.L., Shutter, J.R., Hockenbery, D., Kanagawa, O. & Korsmeyer, S.J. Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 67, 879-888 (1991).
45. Bouillet, P. et al. BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature 415, 922-926 (2002).
46. Calnan, B.J., Szychowski, S., Chan, F.K., Cado, D. & Winoto, A. A role for the orphan steroid receptor Nur77 in apoptosis accompanying antigen-induced negative selection. Immunity 3, 273-282 (1995).
47. Zhou, T. et al. Inhibition of Nur77/Nurr1 leads to inefficient clonal deletion of self- reactive T cells. J. Exp. Med. 183, 1879-1892 (1996).
48. Lunemann, J.D. et al. Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells. J. Immunol. 168, 4881-4888 (2002).
49. Chaudhary, P.M. et al. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway. Immunity 7, 821-830 (1997).
50. Hu, W.H., Johnson, H. & Shu, H.B. Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-κB and JNK activation and apoptosis through distinct pathways. J. Biol. Chem. 274, 30603-30610 (1999).
51. Lin, Y. et al. The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IκB kinase and c-Jun N-terminal kinase. Mol. Cell. Biol. 20, 6638-6645 (2000).
52. Kumar-Sinha, C., Varambally, S., Sreekumar, A. & Chinnaiyan, A. M. Molecular cross-talk between the TRAIL and interferon signaling pathways. J. Biol. Chem. 277, 575-585 (2002).
53. Chen, Y., Inobe, J.-i. & Weiner, H.L. Induction of oral tolerance to MBP in CD8-depleted mice. J. Immunol. 155, 910-916 (1995).